source
- FDA expands Anktiva use for BCG-unresponsive high-grade papillary bladder cancerThe U.S. Food and Drug Administration has broadened the approved use of Anktiva, a therapy given with Bacillus Calmette-Guérin, to treat adults with high-grade papillary-only bladder cancer that ha…
- Verastem reports promising early results for KRAS G12D inhibitor in pancreatic and lung cancersVerastem Oncology has shifted its research toward a KRAS G12D inhibitor, VS-7375, and released early data from a phase 1/2 study involving more than 200 patients with advanced KRAS G12D-mutated sol…